Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.82 |
| ▸ | NT5E | P21589 | 1/20 | 0.77 |
| ▸ | KRAS | P01116 | 5/20 | 0.74 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.73 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.67 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.66 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.66 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17072523 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL37405 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL101367 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL13210265 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18775378 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL23969756 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| Triphosphate SCHEMBL28597197 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18785111 | 1.00 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117618654-A | Antibacterial angiogenesis-promoting nylon6 material and preparation method thereof | 中维化纤股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| WO-2020008209-A1 | TRIPHOSPHORYLATION REACTION | THE UNIVERSITY OF DURHAM (GB) | 2020-01-09 | — | — | WO | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| EP-0090417-B1 | PROCESS FOR PRODUCING 3'-DEOXYGUANOSINE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1989-03-01 | — | — | EP | claimed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | claimed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | claimed |
| JP-4169198-A | — | — | None | — | — | JP | disclosed |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | Lu, Qun (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388620-A1 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5’- CAPPED OLIGONUCLEOTIDES | TRILINK BIOTECHNOLOGIES, LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250215043-A1 | RNA CAP ANALOGS AND METHODS OF USE | MEDICI THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4577553-A2 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5'-CAPPED OLIGONUCLEOTIDES | TriLink BioTechnologies, LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-0189755-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1986-08-06 | — | — | EP | disclosed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | disclosed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | disclosed |
| US-4577012-A | ABSORPTION ON ACTIVATED CARBON, ELUTION WITH ALKALI HYDROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | disclosed |
| US-4297347-A | 3'-DI- OR -TRIPHOSPHATES OF GUANOSINE, URIDINE, AND CYTIDINE | KATSUNUMA NOBUHIKO | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388620-A1 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5’- CAPPED OLIGONUCLEOTIDES | RNGTT, NSUN2, RNMT | TGM2 3990/4885NT5E 327/4885KRAS 1709/4885 |
| US-20250215043-A1 | RNA CAP ANALOGS AND METHODS OF USE | RNGTT, RNMT, NSUN2 | TGM2 3831/4885NT5E 310/4885KRAS 1986/4885 |
| US-20260091009-A1 | ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE | CDC42, GAP43, HASPIN | TGM2 3730/4885NT5E 3988/4885KRAS 337/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | TGM2 2685/4885NT5E 3766/4885KRAS 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.